Hub · Peptide Science
Which peptides are approved in Australia and by the FDA?
The TGA says the Australian Register of Therapeutic Goods (ARTG) lists insulin and semaglutide. It also lists other GLP-1 medicines. It lists oxytocin, desmopressin and octreotide too. This was checked 14 October 2026. Tirzepatide joined the ARTG on 23 December 2022. The TGA report for Mounjaro shows this. The TGA names research peptides such as BPC-157 and retatrutide as unapproved products. It said so on 13 April 2026.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
01Approved in AustraliaContents
Your body makes peptides all day. Insulin moves sugar out of your blood after a meal. It is a peptide. So is oxytocin, which the brain releases during birth and nursing. Peptides are short chains of amino acids. Proteins are made of the same building blocks. Medicine has used this family for about a century.
So one question gets two honest answers. Some peptides are approved medicines with decades of trial records. Many products are sold online as research material. The TGA has not assessed them. Source: TGA peptide products page. This page is part of the peptide science hub. It sorts the two groups using the regulators' own records. It also says what each record cannot show.
Key facts
| Question answered | Which peptides are approved in Australia and by the US FDA |
|---|---|
| Australian register | ARTG, the Australian Register of Therapeutic Goods, kept by the TGA |
| US record used | FDA labels published on DailyMed, the US National Library of Medicine's drug-label database |
| Records checked | 14 October 2026 |
| Approved classes named by the TGA | Insulin and analogues; GLP-1 receptor agonists such as semaglutide; oxytocin; desmopressin; octreotide (TGA guidance) |
| Tirzepatide in Australia | ARTG entry 23 December 2022; weight-management extension 10 September 2024 (TGA AusPAR, finalised 20 September 2024) |
| Tirzepatide in the US | First authorised 13 May 2022 (stated in the TGA AusPAR) |
| Unapproved examples named by the TGA | BPC-157, GHK-Cu, TB-500, retatrutide, CJC-1295 (TGA, 13 April 2026) |
| Research material | Not an approved medicine; not for human or animal use |
What peptides are approved in Australia?
The TGA says the ARTG lists several peptide medicines. These include insulin and insulin analogues. They include glucagon-like peptide-1 (GLP-1) medicines such as semaglutide. They also include oxytocin, desmopressin and octreotide. Source: TGA guidance, checked 14 October 2026. Desmopressin copies vasopressin, a body hormone. Octreotide copies somatostatin, another body hormone. Tirzepatide is the peptide in Mounjaro. It joined the ARTG on 23 December 2022 for type 2 diabetes. A weight-management extension followed on 10 September 2024. Source: TGA report, 20 September 2024. Each approval covers a named product and its stated purpose.
GLP-1 is a hormone your gut releases after a meal. It tells your brain to ease off. Semaglutide and tirzepatide are lab-made peptides that act on that signal. Tirzepatide also acts on a second gut hormone. It is called GIP (Coskun et al., Molecular Metabolism, 2018).
The TGA says these medicines are tested widely in human clinical trials. This happens before approval. It also says many are prescription only. Only authorised health practitioners can prescribe, dispense or supply them. Source: TGA, checked 14 October 2026. Tirzepatide also has a Schedule 4 entry in the October 2026 Poisons Standard. The instrument is F2026L01327, read on 1 October 2026. The Australian law hub records this.
Are peptides available in Australia?
Approved peptide medicines are available in Australia through authorised health practitioners. Many are prescription only. Source: TGA guidance, checked 14 October 2026. You cannot import or supply unapproved peptide products in Australia. The only way round it is a valid exemption. Another way is an approval or an authority. The TGA says a 'research use only' label does not change that. The TGA's overview of 23 September 2026 adds one more point. Many peptide products promoted online are unapproved therapeutic goods. They 'may be unlawful to import, supply or advertise'.
Availability and approval are two different facts. A medicine can be approved and still need a prescription. A product can be easy to find online. It can still be unapproved. The TGA and the Chief Medical Officer made a joint statement on 19 June 2026. They called unapproved peptide products a growing public health risk. They said some have not had enough human clinical trials. That is a health warning, not a legal ruling.
The research reference material on this site is not an approved medicine. It is not a substitute for one. It is not for human or animal use. The Australian law hub sets out the rules for named peptides. These cover Schedule 4, Appendix D, import and sport. Each rule has a check date.
Which peptides are FDA approved now?
The FDA has approved many peptide medicines. This page does not claim a complete list. Labels on DailyMed show these years for Initial U.S. Approval. They were checked 14 October 2026. Tirzepatide is 2022 (Mounjaro label). Semaglutide is 2017 (Ozempic label). Tesamorelin is 2010 (Egrifta label). Octreotide is 1988 (octreotide acetate label). Human insulin is 1982 (Humulin R label. Desmopressin is 1978 (desmopressin acetate label). Each year is the one printed on the label itself. A 2021 review counted more than 80 peptide drugs on sale worldwide (Muttenthaler et al., 2021). A 2022 review counted 33 non-insulin peptide drugs. These were approved worldwide since 2000 (Wang et al., 2022). Both counts come from reviews of the literature. They do not come from a regulator's register.
FDA approval covers a product and its labelled use. It does not cover a molecule's name. Compounding is a separate US pathway. It is where a pharmacy mixes a medicine for one patient. The FDA's section 503A page, current as of 14 May 2026, sets the limit. A compounder may use only three kinds of bulk substance. The first kind meets a pharmacopoeia monograph. The second is a part of an FDA-approved drug. The third appears on the 503A bulks list.
A peptide under discussion is not a peptide approved. The FDA held an advisory committee meeting. It took place on 23 and 24 July 2026. Its agenda lists seven peptides for the 503A bulks list. They are BPC-157, KPV, TB-500, MOTs-C, emideltide, semax and epitalon. Source: FDA meeting page, checked 14 October 2026. The FDA says advisory committees make non-binding recommendations. The Australian law hub covers the FDA compounding lists in more detail. How retatrutide differs from Mounjaro and Ozempic compares an unapproved molecule with approved medicines.
Does an approval record say a peptide is worth taking?
No. An approval record describes a medicine and its stated use. It does not decide what is right for each reader. A study also has a measured goal, such as weight change. Worth taking is not that measured goal. These are different questions, even when they name the same peptide.
The FDA tesamorelin label makes the boundary clear. It covers excess belly fat. This is in adults with HIV and altered fat distribution. It excludes general weight-loss management (FDA label, 2025; checked 17 October 2026). A label can include one use and rule out another.
The FDA safety list is a different kind of record. It flags concerns about CJC-1295 and ipamorelin, checked 17 October 2026. It does not rank them for personal value. Neither record measures whether an unknown reader should take a peptide.
How does an approved peptide medicine differ from a research peptide?
A regulator has checked an approved peptide medicine. The checks cover quality, safety and effectiveness. No regulator has checked a research peptide. The TGA says it has not checked unapproved peptide products for safety, quality or effectiveness. So nothing assures you they are labelled correctly. Nothing assures you they are sterile. Nothing assures you they are made to proper quality standards. Source: TGA peptide products page, 23 September 2026. The two can share a molecule name. They can still differ. The differences are in how they are made, tested and labelled. The evidence reviewed can differ too. An approval speaks for one product. It covers one labelled use and one body of evidence.
The TGA's alert of 14 September 2026 shows why the difference matters. The TGA tested one sample of a product sold as retatrutide. The sample came after a serious adverse event report. The test found semaglutide that was not declared and no retatrutide. That result describes that sample, not other products. Source: TGA alert. Retatrutide's legal status in Australia has the full record.
The FDA made the same point about labels. It did so in warning letters to online sellers. The letters are dated 24 August 2026. One letter says words such as 'research use only' did not change one fact. The seller's products were still intended to be drugs for human use. It lists products including retatrutide as unapproved new drugs. Source: FDA letter 734884.
Two names show the split. The TGA lists BPC-157 and retatrutide among its examples of unapproved peptide products. Source: TGA, 13 April 2026. The BPC-157 research guide and the retatrutide research guide describe the published studies. Each covers one compound. A study record is not an approval.
What did FDA and TGA say about research-use labels in 2026?
Both agencies made one point. A research-use label does not settle the product question. The FDA looked at human-use claims in a March warning letter. The TGA says the label does not change whether medicine rules apply. This is about a product. We checked these records on 17 October 2026. Neither agency treats a research label as medicine approval.
The FDA letter of 31 March 2026 looked at the website and the research label together. Its finding was about that website and the claims it made. A short label could not erase those claims.
The TGA regulation page sets out the Australian position, checked 17 October 2026. Research-use wording does not remove the duties for import, supply or advertising. The FDA letter and the TGA guidance come from two separate national systems. They agree on one narrow point. The wording alone does not settle status.

Evidence limits
What can this page not show?
This page is not a complete list of approved peptides in either country. It reads TGA pages and one TGA public assessment report. It also reads six FDA labels on DailyMed. We checked all of them on 14 October 2026. It did not count ARTG entries. It did not check every FDA approval. Later records may differ. It states no legal position for any person. It does not say a research peptide is lawful for a particular use. It does not say it is unlawful either. The answer depends on the substance, the product and the activity.
Initial U.S. Approval is a line printed on a label. It shows the first year the active ingredient was approved. The label gives that year. It says nothing about current supply. Scheduling under the Poisons Standard is one question. TGA approval is another. State or territory law is a third. Each has its own record.
Comparison
Peptide medicines checked in both countries on 14 October 2026. The Australian column quotes the TGA or its public assessment report. The US column quotes the Initial U.S. Approval line on a DailyMed label. This is not a complete list.
| Peptide medicine | Australia: TGA record | United States: DailyMed label |
|---|---|---|
| Semaglutide: a GLP-1 receptor agonist | Named by the TGA as an approved peptide medicine class example | Ozempic label: Initial U.S. Approval 2017 |
| Tirzepatide: acts on GIP and GLP-1 receptors | Mounjaro: ARTG entry 23 December 2022; weight-management extension 10 September 2024 (TGA report, 20 September 2024) | Mounjaro label: Initial U.S. Approval 2022 |
| Octreotide: a somatostatin analogue | Named by the TGA as an approved peptide medicine class example | Octreotide acetate label: Initial U.S. Approval 1988 |
| Desmopressin: a vasopressin analogue | Named by the TGA as an approved peptide medicine class example | Desmopressin acetate label: Initial U.S. Approval 1978 |
| Human insulin | Insulin and insulin analogues named by the TGA as approved | Humulin R label: Initial U.S. Approval 1982 |
FAQ
Are peptides available in Australia?
Approved peptide medicines are available through authorised health practitioners. Many are prescription only. Source: TGA guidance, checked 14 October 2026. Unapproved peptide products cannot be imported or supplied. The exception is when a valid exemption, approval or authority applies.
Is retatrutide approved in Australia or by the FDA?
No. The TGA made a statement on 14 September 2026. It said it has not approved retatrutide. No comparable international regulator has either. Source: TGA alert, 14 September 2026.
Is BPC-157 an approved medicine?
The TGA names BPC-157 as an example of an unapproved peptide product. Source: TGA alert, 13 April 2026. The FDA lists BPC-157 among nominated bulk drug substances. That is a different list from approved drugs. Source: FDA page, 22 April 2026.
Does 'research use only' make a peptide approved or lawful?
No. The TGA says 'research use only' and 'not for human use' notes do not change one thing. The product is still regulated as a therapeutic good. They also do not remove import, supply or advertising obligations. Source: TGA guidance.
Are approved peptide medicines prescription-only in Australia?
Many are. The TGA says many approved peptide medicines can only be prescribed, dispensed or supplied. Only authorised health practitioners can do this. They also cannot generally be advertised to the public. Source: TGA, checked 14 October 2026.
More in this hub
- Is SLU-PP-332 a peptide, and what harm record exists?
- What is SS-31, and did its trial measure weight loss?
- What are peptides? Meaning, medicines, safety and legal status in Australia
- What is a peptide bond? Peptide structure, chemistry and synthetic peptides explained
- Citrullinated peptide antibodies: what anti-CCP is, why the test peptide is cyclic and how it is pronounced
- Peptide vs protein: what is the difference? Peptides compared with proteins, hormones, collagen and approved medicines
- What do peptides do? What published studies found
- Peptide side effects: what studies and regulators have recorded
- Do peptides show up on drug tests? How peptides are tested and labelled
- What have collagen peptide studies measured about muscle?
- What is a signal peptide, and how does it direct a protein?
- What is carnosine, and what do studies measure?
- What is CGRP, and how does its signalling work?
- What is icotrokinra, and what do receptor studies measure?
- What is irisin, and how is it studied?
- What is lunasin, and what have studies measured?
- What is pramlintide, and how does amylin signalling work?
- What is peptide YY, and what do studies measure?
- What does TAT-DATNT refer to in peptide research?
Citations
3 sourcesMuttenthaler M et al. Nature Reviews Drug Discovery. 2021;20(4):309-325.
doi:10.1038/s41573-020-00135-8Wang L et al. Signal Transduction and Targeted Therapy. 2022;7:48.
doi:10.1038/s41392-022-00904-4Coskun T et al. Molecular Metabolism. 2018;18:3-14.
doi:10.1016/j.molmet.2018.09.009
Continue
Research compound catalogueResearch use only, not for human or animal use.
Read the Australian law guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.
